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Abstract
Introduction: SPARC is a matricellular protein, which, along with other extracellular matrix components including 
collagens, is commonly over-expressed in fibrotic diseases. The purpose of this study was to examine whether 
inhibition of SPARC can regulate collagen expression in vitro and in vivo, and subsequently attenuate fibrotic stimulation 
by bleomycin in mouse skin and lungs.
Methods: In in vitro studies, skin fibroblasts obtained from a Tgfbr1 knock-in mouse (TBR1CA; Cre-ER) were transfected 
with SPARC siRNA. Gene and protein expressions of the Col1a2 and the Ctgf were examined by real-time RT-PCR and 
Western blotting, respectively. In in vivo studies, C57BL/6 mice were induced for skin and lung fibrosis by bleomycin 
and followed by SPARC siRNA treatment through subcutaneous injection and intratracheal instillation, respectively. The 
pathological changes of skin and lungs were assessed by hematoxylin and eosin and Masson's trichrome stains. The 
expression changes of collagen in the tissues were assessed by real-time RT-PCR and non-crosslinked fibrillar collagen 
content assays.
Results: SPARC siRNA significantly reduced gene and protein expression of collagen type 1 in fibroblasts obtained from 
the TBR1CA; Cre-ER mouse that was induced for constitutively active TGF-β receptor I. Skin and lung fibrosis induced by 
bleomycin was markedly reduced by treatment with SPARC siRNA. The anti-fibrotic effect of SPARC siRNA in vivo was 
accompanied by an inhibition of Ctgf expression in these same tissues.
Conclusions: Specific inhibition of SPARC effectively reduced fibrotic changes in vitro and in vivo. SPARC inhibition may 
represent a potential therapeutic approach to fibrotic diseases.
Introduction
Fibrosis is a general pathological process in which exces-
sive deposition of extracellular matrix (ECM) occurs in
the tissues. It is currently untreatable. Although thera-
peutic uses of some anti-inflammatory and immunosup-
pressive agents such as colchicine, interferon-gamma,
corticosteroids and cyclophosphamide have been
reported, many of these approaches have not proven suc-
cessful [1-3]. Recently, SPARC (secreted protein, acidic
and rich in cysteine), a matricellular component of the
ECM, has been reported as a bio-marker for fibrosis in
multiple fibrotic diseases, such as interstitial pulmonary
fibrosis, renal interstitial fibrosis, cirrhosis, atheroscle-
rotic lesions and scleroderma or systemic sclerosis (SSc)
[4-9]. Notably, increased expression of SPARC has been
observed in affected skin and circulation of patients with
SSc [10,11], a devastating disease of systemic fibrosis, as
well as in cultured dermal fibroblasts obtained from SSc
skin [8,9].
SPARC, also called osteonectin or BM-40, is an impor-
tant mediator of cell-matrix interaction [12]. Increasing
evidence indicates that SPARC may play an important
role in tissue fibrosis. In addition to its higher expression
level in the tissues of fibrotic diseases, SPARC has shown
a capacity to stimulate the transforming growth factor
beta (TGF-β) signaling system [13]. Inhibition of SPARC
attenuates the profibrotic effect of exogenous TGF-β in
cultured human fibroblasts [14]. Moreover, in animal
studies, SPARC-null mice display a diminished amount of
pulmonary fibrosis compared with control mice after
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with a profibrotic effect [15]. These observations suggest
that SPARC is a potential bio-target for anti-fibrotic ther-
apy.
Recently, application of double-stranded small interfer-
ing RNA (siRNA) to induce RNA silencing in cells has
been widely accepted in many studies of gene functions
and potential therapeutic targets [16]. The selective and
robust effect of RNAi on gene expression makes it a valu-
able research tool, both in cell culture and in living organ-
isms. Unlike a gene knockout method, siRNA-based
technology can easily silence the expression of a specific
gene and is more feasible in practice, such as in disease
therapy. Therefore, tissue-specific administration of the
siRNA of candidate genes is currently being developed as
a potential therapy in a great number of diseases, such as
pulmonary diseases, ocular diseases, and others [17-19].
Our previous studies demonstrated that the overproduc-
tion of collagens in the fibroblasts obtained from SSc skin
can be attenuated through SPARC silencing with siRNA.
It suggested that application of SPARC silencing repre-
sents a potential therapeutic approach to fibrosis in SSc
and other fibrotic diseases [20]. However, it is still
unknown whether SPARC siRNA can improve fibrotic
manifestations in vivo. The main purpose of the studies
herein was to explore the feasibility of inhibition of
SPARC with siRNA to counter fibrotic processes in a
fibrotic mouse model in vivo. As a preliminary experi-
ment in the in vivo studies, the fibroblasts cultured from a
transgenic fibrotic model were used to assess the possibil-
ity and potential mechanisms of SPARC siRNA in attenu-
ating the collagen expression in vitro. At the same time,
the effects of SPARC siRNA to encounter fibrosis were
compared with that of siRNA of CTGF, a well-known
fibrotic marker. The fibrotic models used herein were the
very popular bleomycin-induced skin and pulmonary
fibrosis in mice. Subcutaneous injection and intratracheal
instillation of siRNAs were used for tissue-specific treat-
ments of skin and pulmonary fibrosis, respectively.
Materials and methods
Fibroblast cell lines from Tgfbr1 knock-in mouse
Constitutively activated Tgfbr1 mice, which recapitulated
clinical, histological, and biochemical features of human
SSc, have been reported previously [21]. They are termed
TBR1CA; Cre-ER mice and harbor both the DNA for an
inducible constitutively active TGFβ receptor I (TGFβRI)
mutation targeted to the ROSA locus, and a Cre-ER
transgene driven by a Col1 fibroblast-specific promoter.
Fibroblasts were derived from skin biopsy specimens of
these mice. The cultures were maintained in DMEM with
10% FCS and supplemented with antibiotics (50 U/ml
penicillin and 50 μg/ml streptomycin). Fifth-passage
fibroblast cells were seeded at a density of 5 × 105 cells in
25-cm2 flasks and grown until confluence. Experiments
were performed in triplicates.
Transient transfection with siRNA in fibroblasts
Double-stranded ON-TARGETplus siRNAs of murine
SPARC and Ctgf were purchased from Dharmacon, Inc.
(Lafayette, CO, USA). The corresponding target
sequences are 5'-GCACCACACGUUUCUUUG-3' for
SPARC and 5'-GCACCAGUGUGAAGACAUA-3' for
Ctgf, respectively. The culture medium in each culture
flask with confluent fibroblasts was replaced with Opti-
MEM I medium (Invitrogen, Carlsbad, CA, USA) without
FCS and antibiotics. The fibroblasts were incubated for
24 hours and transfected with SPARC siRNA or Ctgf
siRNA in a concentration of 100 nmol/L, using Dharma-
FECT™ 1 siRNA Transfection Reagent (Dharmacon).
Fibroblasts with Non-Targeting siRNA (Dharmacon)
treatment were used as negative controls. The non-tar-
geting siRNA was characterized by genome-wide
microarray analysis and found to have minimal off-target
signatures to human cells. It targets firefly luciferase
(U47296). After 24 hours, the culture medium was
replaced with DMEM. The cells transfected with siRNA
were examined after 72 hours of transfection and used for
RNA and protein expression analysis. The experiments
were performed in triplicates.
Animal models of fibrosis
C57BL/6 mice of about 20 grams were purchased from
Jackson Laboratory (Bar Harbor, ME, USA). Bleomycin
from Teva Parenteral Medicines Inc. (Irvine, CA, USA)
was dissolved in saline and used in the mice at a concen-
tration of 3.5 units/kg. Pulmonary fibrosis was induced in
these mice with one time intratracheal instillation of
bleomycin. For dermal fibrosis, female C57BL/6 mice at
six weeks (weighing about 20 g) were treated daily for
four weeks with local subcutaneous injection of 100 μl
bleomycin in the shaved lower back. Four mice were used
in each group. The animal protocols were approved by
the Center for Laboratory Animal Medicine and Care in
the University of Texas Health Science Center at Hous-
ton, the Institutional Animal Use and Care Committee of
M.D. Anderson Cancer Center, and Fudan University,
China.
Administration of siRNAs in vivo
For pulmonary fibrosis, 3 μg of siRNA for in vivo use (siS-
TABLE, Dharmacon), mixed with DharmaFECT™ 1
siRNA Transfection Reagent, was administrated intratra-
cheally in 60 μl on Days 2, 5, 12 after bleomycin treat-
ment. In addition, the siGLO Green transfection
indicator (Dharmacon), a fluorescent RNA duplex was
used for evaluating distribution of intratracheally injected
siRNA. Twenty-four hours after injection, lung tissues
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tomy. All the mice were sacrificed on Day 23 after anes-
thesia, and the lung samples were collected. The left
lungs were fixed by 4% formalin and used for further his-
tological analysis. The right lungs were minced to small
pieces and divided into two parts, one for RNA extraction
and one for collagen content analysis.
For dermal fibrosis, the above siRNAs were injected
into the same area as that of bleomycin three hours after
bleomycin treatment and continued for four weeks. The
mice were sacrificed on Day 29 and the skin samples were
collected. Saline was used as a negative control in both
fibrosis studies.
Determination of gene expression by quantitative RT-PCR
Total RNA from each cell line was extracted from the cul-
tured fibroblasts using RNeasy Mini Kit (Qiagen, Valen-
cia, CA, USA). For mice lung and skin tissues, the minced
samples were homogenized in lysis solution (Sigma-
Aldrich, St. Louis, MO, USA) with a blender. Then total
RNA was extracted using GenElute™ Mammalian Total
RNA Miniprep Kit (Sigma-Aldrich). Complementary
DNA (cDNA) was synthesized using MultiScribe™
Reverse Transcriptase (Applied Biosystems, Foster city,
CA, USA). Quantitative real-time RT-PCR was per-
formed using an ABI 7900 Sequence Detector System
(Applied Biosystems). The specific primers and probes
for each gene (Col1a2, Col3A1, Ctgf, SPARC and Ccl2)
were purchased from the Assays-on-Demand product
line (Applied Biosystems). Synthesized cDNAs were
mixed with primers/probes in 2 × TaqMan universal PCR
buffer and then assayed on an ABI 7900 sequence detec-
tor. The data obtained from the assays were analyzed with
SDS 2.2 software (Applied Biosystems). The expression
level of each gene in each sample was normalized with
Gapdh transcript level.
Western blot analysis
The lysis buffer for Western blot analysis consisted of 1%
Triton X-100, 0.5% Deoxycholate Acid, 0.1% SDS, 1 mM
EDTA in PBS and proteinase inhibitor cocktail from
Roche (Basel, Switzerland). The cellular lysates extracted
from the cultured fibroblasts were used for protein
assays. The protein concentration was determined by a
spectrophotometer using Bradford protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA). Equal amounts of
protein from each sample were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis.
Resolved proteins were transferred onto PVDF mem-
branes and incubated with respective primary antibodies,
including anti-type I collagen antibody (Biodesign Inter-
national, Saco, ME, USA), anti-CTGF antibody (GeneTex
Inc, San Antonio, TX, USA), and anti-SPARC antibody
(R&D Systems Inc, Minneapolis, MN, USA). Mouse β-
actin (Alexis Biochemicals, San Diego, CA, USA) was
used as an internal control. The secondary antibody was
peroxidase-conjugated anti-rabbit, anti-goat, or anti-
mouse IgG. Specific proteins were detected by chemilu-
minescence using an enhanced chemiluminescence sys-
tem (Amersham, Piscataway, NJ, USA). The intensity of
the bands was quantified using ImageQuant software
(Molecular Dynamics, Sunnyvale, CA, USA).
Determination of collagen content
Non-crosslinked fibrillar collagen in lung samples and
skin samples was measured using the Sircol colorimetric
assay (Biocolor, Belfast, UK). Minced tissues were
homogenized in 0.5 M acetic acid with about 1:10 ratio of
pepsin (Sigma-Aldrich). Tissues were weighted, and then
incubated overnight at 4°C with vigorous stirring.
Digested samples were centrifuged and the supernatant
was used for the analysis with the Sircol dye reagent. The
protein concentration was determined using Bradford
protein assay kits and the collagen content of each sample
was normalized to total protein.
Histological analysis
The tissue samples of both lung and skin were fixed in 4%
formalin and embedded in paraffin. Sections of 5 μm
were stained either with hematoxylin and eosin (HE) and
Masson's trichrome.
Statistical analysis
Results were expressed as mean ± SD). The difference
between different conditions or treatments was assessed
by Student's t-test. A P-value of less than 0.05 was consid-
ered statistically significant.
Results
Gene and protein expression of Col1a2, Ctgf and SPARC in 
the fibroblasts from TBR1CA; Cre-ER mice with and without 
transfection of siRNAs of SPARC or Ctgf
As measured by quantitative real-time RT-PCR, the tran-
scripts of Col1a2, Ctgf and SPARC showed increased
expression in the fibroblasts from TBR1CA; Cre-ER mice
injected with 4-OHT, in which Tgfbr1 was constitutively
active, compared with those in the cells from TBR1CA;
Cre-ER mice injected with oil (Figure 1). The fold-
changes of each gene in 4-OHT-injected TBR1CA; Cre-ER
mice fibroblasts were 3.06 ± 1.42 for Col1a2 (P = 0.050),
4.15 ± 1.18 for Ctgf (P = 0.049), and 2.49 ± 0.63 for SPARC
(P = 0.017), respectively. To study whether inhibition of
SPARC induced a reduction of collagen in the fibroblasts
from constitutively active Tgfbr1 mice, we transfected
SPARC siRNA into cultured fibroblasts obtained from
TBR1CA; Cre-ER mice injected with 4-OHT. Ctgf is a
down-stream gene in the TGF-β pathway [22-25], and
inhibition of Ctgf reduced expression of the fibrotic effect
Wang et al. Arthritis Research & Therapy 2010, 12:R60
http://arthritis-research.com/content/12/2/R60
Page 4 of 9of TGF-β [26]. We used Ctgf siRNA as a positive control
for inhibition of Ctgf and collagen expression. Transfec-
tion efficiency of siRNAs into fibroblasts was measured
using fluorescent RNA duplex siGLO Green transfection
indicator (Dharmacon) and was determined to be over
80%. The gene expression levels from the Non-Targeting
siRNA treated fibroblasts were compared with those
from saline-treatment fibroblasts, and no significant dif-
ferences were found (1.05 ± 0.18-folds for Col1a2, 1.14 ±
0.16-folds for Ctgf, and 1.12 ± 0.12-folds for SPARC).
Therefore, in the following in vitro study, fibroblasts with
Non-Targeting siRNA treatment were used as negative
controls. Seventy-two hours after SPARC siRNA or Ctgf
siRNA transfection, significant reductions of SPARC
(95%) by SPARC siRNA and Ctgf (64%) by Ctgf siRNA
were observed in the fibroblasts (Figure 2A). In parallel,
Col1a2 showed decreased expression in both siRNA
transfected fibroblasts (27% and 29% decrease with P <
0.05 for Ctgf siRNA and SPARC siRNA, respectively)
(Figure 2A). Western blot analysis showed a similar level
of protein reduction of type I collagen by either SPARC
siRNA or Ctgf siRNA treatment. As illustrated in Figure
2B, C, both SPARC siRNA and Ctgf siRNA showed signif-
icant attenuation of collagen type I in the fibroblasts (P =
0.009 or 0.015, respectively). CTGF and SPARC protein
levels also were reduced by their corresponding siRNAs
(P = 0.002 and 0.0004, respectively).
siRNAs of SPARC and Ctgf ameliorated fibrosis in skin and 
reduced inflammation in lungs induced by bleomycin
HE stains of mouse skin tissues (Figure 3-1) showed that
four-week injections of bleomycin induced significant
fibrosis in skin where the fat cells were replaced by fiber
bundles (Figure 3-1B, compared with normal skin
injected with saline only (Figure 3-1A). Bleomycin-
injected skin treated with SPARC siRNA or Ctgf siRNA
showed that most of the fat cells still existed in the dermis
without prominent fiber bundles (Figure 3-1C, D). Mas-
son's trichrome staining of the samples also showed the
same results. Notably, increased hair follicles were incon-
sistently seen in Ctgf siRNA- and SPARC siRNA-treated
bleomycin-induced skins.
The lung distribution of intratracheally injected fluo-
rescent siRNA showed that intense fluorescence was dis-
tributed within epithelial cells of bronchi and
bronchioles, and only weak fluorescence was detected in
the parenchyma (Figure 4-1).
HE stain of mouse lung tissues (Figure 4-2) showed a
significant disruption of the alveolar units and infiltration
of inflammatory cells in the lungs induced by bleomycin
(Figure 4-2B), compared with saline injection (Figure 4-
2A). However, after treatment with Ctgf siRNA or SPARC
siRNA, the disruption of the alveoli was improved with
less infiltrating inflammatory cells (Figure 4-2C, D). In
addition, both siRNA treatments showed a significant
reduction of gene expression of Ccl2, an active biomaker
Figure 2 Gene and protein expression in original and siRNA treat-
ed fibroblasts from TBR1CA; Cre-ER mice injected with 4-OHT. (A) 
Relative transcript levels of Col1a2, Ctgf, and SPARC in cultured fibro-
blasts transfected with non-targeting siRNA (NT siRNA), Ctgf siRNA and 
SPARC siRNA. The expression level of each gene in the fibroblast lines 
with NT siRNA transfection was normalized to 1. *, P < 0.05. (B) Western 
blot analysis of type I collagen (COL1), CTGF, and SPARC in the fibro-
blasts from constitutively active Tgfbr1 mice transfected with NT siR-
NA, Ctgf siRNA or SPARC siRNA. N, non-targeting siRNA transfected 
fibroblasts; C, Ctgf siRNA transfected fibroblasts; S, SPARC siRNA trans-
fected fibroblasts. (C) Densitometric analysis of Western blots for pro-
tein level of COL1, CTGF, and SPARC. Compared to non-targeting 
siRNA treatment, Ctgf siRNA or SPARC siRNA transfected fibroblasts 
showed significant reduction of COL1 (P = 0.015 or 0.009 respectively). 
Significant reduction of CTGF (P = .002) by Ctgf siRNA and SPARC (P = 
0.0004) by SPARC siRNA were also shown. Bars show the mean ± SD re-
sults of analysis of three independent experiments performed in tripli-
cate. *, P < 0.05.
Figure 1 Comparison of gene expression between the fibroblasts 
of TBR1CA; Cre-ER mice injected with oil and 4-OHT. The expression 
level of each gene in the fibroblasts of TBR1CA; Cre-ER mice injected 
with oil was normalized to 1. Bars show the mean ± SD results of anal-
ysis of three independent experiments performed in triplicate. *, P < 
0.05.
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stimulated mice (Figure 5B).
siRNAs of SPARC and Ctgf reduced the collagen contents in 
bleomycin-induced mouse skin and lung tissues
To further evaluate anti-fibrotic effects of siRNAs on the
fibrogenesis of skin and lung, the collagen content was
measured in the collected dermal and pulmonary sam-
ples. Quantification of total collagen in skin samples with
the Sircol assay showed a 2.2-fold increase in bleomycin-
induced skin compared with saline-injected skin (P =
0.050). Ctgf siRNA treatment reduced the collagen con-
tent significantly to 47.6% (P = 0.028) of that in bleomy-
Figure 3 Examination of skin tissues. (1) Representative histological analysis of HE and Trichrome stain of mouse skin with different treatments for 
four weeks in low (4 ×) and high magnifications (20 ×). Four mice were used for each group. A. Injection with saline (negative control) only; B. Injection 
with bleomycin only; C. Injection with bleomycin and treatment with SPARC siRNA; D. Injection with bleomycin and treatment with Ctgf siRNA. (2) 
Collagen contents in skin samples with different treatments. The collagen content in the skin sample from saline treated mice was normalized to 1. 
Treatments: Sa, saline; B, bleomycin; B + C, bleomycin and Ctgf siRNAs; B + S, bleomycin and SPARC siRNA. P < 0.05.
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Figure 4 Examination of lung tissues. (1) The lung tissue staining for intratracheally injected fluorescent siRNA. Intense fluorescence was observed 
within epithelial cells of bronchi and bronchioles, and weak fluorescence was detected in the parenchyma. (2) Representative histological features of 
HE and Trichrome stain of mouse lung samples with different treatments intratracheally in low (4 ×) and high magnifications (40 ×). Four mice were 
used for each group. A. Injection with saline (negative control) only; B. Injection with bleomycin only on Day 0; C. Injection with bleomycin on Day 0 
and SPARC siRNA on Days 2, 5, and 12; D. Injection with bleomycin on Day 0 and Ctgf siRNA on Days 2, 5, and 12. (3) Collagen contents in lung samples 
with different treatments. The collagen content in the lung sample from saline treated mice was normalized to 1. Four mice were used for each group. 
Treatments: Sa, saline; B, bleomycin; B + C, bleomycin and Ctgf siRNAs; B + S, bleomycin and SPARC siRNA. *, P < 0.05.
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the collagen content to 64.6% (P = 0.077) but not very sig-
nificantly (Figure 3-2). The difference of collagen reduc-
tion (P = 0.076) between SPARC siRNA treatment and
Ctgf siRNA treatment was not very significant might due
to the small sample size.
The siRNA treatments also showed a reduction of col-
lagen in the lung tissues of bleomycin-induced mice (Fig-
ure 4-2). In bleomycin-induced mice, collagen content of
lung tissues was 3.6-fold higher than that in saline-
injected control mice (P = 0.014). In SPARC siRNA
treated mice that also were bleomycin-induced, the colla-
gen content of lung tissues was significantly reduced to
58% (P = 0.019) of that in bleomycin-induced mice with-
out siRNA treatment. Ctgf siRNA also reduced the colla-
gen content to a quite low level (68% of that without
siRNA treatment) but without significance (P = 0.128).
Further, no significant difference of collagen content was
found between SPARC siRNA treatment and Ctgf siRNA
treatment in bleomycin-injured lungs (P = 0.277).
siRNAs of SPARC and Ctgf attenuated over-expression of 
collagen and other fibrotic ECM genes induced by 
bleomycin in skin and lung tissues
Bleomycin injection induced an up-regulation of the
Col1a2, Col3a1, Ctgf and SPARC gene in both skin (Fig-
ure 5A, P = 0.028, 0.016, 0.049 and 0.0005, respectively)
and lung tissues (Figure 5B, P = 0.015, 0.005, 0.041 and
0.056, respectively) of the mice significantly or marginal
significantly. However, in Ctgf siRNA or SPARC siRNA
treated mice skin that also received bleomycin injection,
the expression of the Col1a2 and Col3a1 appeared to be
normal in skin tissues (Figure 5A, P = 0.025 and 0.003 for
each gene in Ctgf siRNA treatment, and P = 0.031 and
0.010 in SPARC siRNA treatment), and were significantly
improved in lung tissues (about 2.7-fold reduction for
Col1a2 and 1.9-fold reduction for Col3a1, compared to
bleomyin-injected mice without siRNA treatment, P <
0.05 for both) (Figure 5B). In addition to collagen gene
expression, the Ctgf and the SPARC expression were sig-
nificantly or marginal significantly reduced by SPARC
siRNA and Ctgf siRNA treatment, respectively (Figure
5B). In detail, compared to bleomycin-induced skin and
lungs, SPARC siRNA normalized Ctgf expression in both
skin and lungs (2.6-fold reduction in both with P = 0.100
and 0.039, respectively). Similarly, Ctgf siRNA also
reduced SPARC expression in skin and lungs (2.9-fold
and 1.5-fold reduction with P = 0.044 and 0.102, respec-
tively).
Discussion
Although fibrosis is usually an irreversible pathological
condition, targeting underlying molecular effectors may
reverse an active status of the fibrotic process, and subse-
quently inhibit fibrosis. The TGF-β signaling pathway is
associated with active fibrosis [22,23]. It begins with the
binding of the TGF-β ligand to the TGF-β type II recep-
tor, which catalyses the phosphorylation of the type I
receptor on the cell membrane. The type I receptor then
induces the phosphorylation of receptor-regulated
SMADs (R-SMADs) that bind the coSMAD. The phos-
phorylated R-SMAD/coSMAD complex enters the
nucleus acting as transcription factors to regulate target
gene expression [22,23]. CTGF (connective tissue growth
factor) is a down-stream gene that can be activated by the
TGF-β signaling pathway [23,24]. Activation of CTGF is
associated with potent and persistent fibrotic changes in
the tissues, which is typically represented as accumula-
tion of the ECM components including collagens [24,25].
SPARC also is involved in TGF-β signaling. It was
reported that SPARC stimulated Smad2 phosphorylation
and Smad2/3 nuclear translation in lung epithelial cells
[27]. Recently, while examining SPARC regulatory role on
the ECM components in human fibroblasts using linear
structure equations, we demonstrated that SPARC posi-
tively controlled the expression of CTGF [26]. Although
down-regulation of CTGF has been employed in treating
fibrotic conditions [28], application of SPARC inhibition
in attenuation of a fibrotic process in a therapeutic animal
model has not been reported.
Figure 5 Gene expression in skin (A) or lung samples (B) with dif-
ferent treatments. Four mice were used for each treatment. The rela-
tive transcript levels of Col1a2, Col3a1, Ctgf, SPARC and Ccl2 in siRNA-
treated or untreated bleomycin-induced skins or lungs, respectively. 
The expression level of each gene in the skin or lung sample from sa-
line treated mice was normalized to 1. Treatments: Saline; BLM (bleo-
mycin); BLM + Ctgf siRNA and BLM + SPARC siRNA. *, P < 0.05.
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obtained from the TBR1CA; Cre-ER mice that were
induced for constitutively active TGF-β receptor I. After
transfection of SPARC siRNA, the fibroblasts showed a
decreased expression of Col1a2 that was originally over-
expressed in the TBR1CA; Cre-ER mice (Figure 2). This
phenomenon suggests that SPARC inhibition may inter-
rupt fibrotic TGF-β signaling, which generally induces
collagen production. Although the specific mechanism
for this suppression is unclear, multiple previous studies
have demonstrated a mutual regulatory relationship
between SPARC and TGF-β signaling [14,26,29]. This
notion also is supported by the observation of an over-
expression of SPARC in the fibroblasts of the TBR1CA;
Cre-ER mice (Figure 1). It should be noted that the Ctgf
expression in the fibroblasts was not reduced upon
SPARC inhibition. These results appear to contradict our
previous report of parallel inhibition of SPARC and
CTGF expression in human fibroblasts by SPARC siRNA
[14]. A possible explanation is that over-expressed Ctgf
from constitutively activated TGF-β signaling in these
fibroblasts may confer resistance to a down-regulatory
effect from SPARC siRNA. However, such resistance
appeared to have limited influence on any down-regula-
tory effect of SPARC siRNA on collagen type 1, which
suggests that CTGF is not a sole contributor to TGF-β
signaling-associated fibrosis.
Bleomycin induced fibrosis in mice usually occurs after
inflammation in which TGF-β is up-regulated [30]. Our
in vivo application of SPARC siRNA demonstrated that
inhibition of SPARC significantly reduced fibrosis in skin
and lungs induced by bleomycin. In the treatment of skin
fibrosis, SPARC siRNAs reduced fiber bundles accumu-
lated in the dermis with less mononuclear cell infiltrates
(Figure 3-1). In addition to histological changes, the
thickness of bleomycin-induced skin treated with SPARC
siRNA showed over 50% reduction compared to that
without SPARC siRNA treatment (data not shown). The
changes of tissue fibrotic level further were confirmed
with significantly decreased collagen gene expression
(Figure 5A). Non-crosslinked fibrillar collagen in the skin
tissues also showed an average of 35.4% reduction after
SPARC siRNA treatment (Figure 3-2).
In the treatment of lungs, SPARC siRNA reduced the
disruption and inflammatory cells of the alveoli induced
by bleomycin (Figure 4-2), which was accompanied with
attenuated gene expression and protein content of colla-
gens as compared to that without siRNA treatment (Fig-
ures 5B and 4-3). In addition, a significant reduction of
the Ccl2 expression in the siRNA-treated lung tissues also
suggests an improvement of inflammation supporting the
findings in histological staining. These observations are
consistent with previous reports on SPARC-null mice
that exhibited attenuation of inflammation and fibrosis in
kidneys [31]. While precise mechanism of these changes
is still unknown, increased expression of SPARC was
reported to correlate with the levels of inflammatory
markers [32,33]. It is likely that SPARC inhibition altered
composition of microenvironment of the tissues that may
restrain inflammatory response. On the other hand,
much higher levels of gene expression of Col1A2 and
Col3A1, and protein content of collagen were observed in
bleomycin-induced lung tissues when they were com-
pared to that in skin tissues (5.2-fold, 6.7-fold and 3.6-fold
increase vs. 3.8-fold, 2.8-fold and 2.2-fold increase,
respectively), which suggested that tissue damage and
fibrosis in lung might be more severe than that in skin. In
this case, treatment of bleomycin-induced lung damage
might present a bigger challenge than that of skin, and the
siRNA treatment through intratracheal instillation may
be in need of further optimization. These notions were
supported by similar findings in the treatment with the
Ctgf siRNA, a positive control for anti-fibrotic effects.
Nevertheless, SPARC inhibition showed a clear anti-
fibrotic effect in bleomycin-induced skin and lung tis-
sues. Notably, these changes were accompanied with a
significant down regulation of Ctgf that paralleled with
Ctgf up-regulation in bleomycin-induced tissues. Thus,
SPARC might regulate the collagen expression through
affecting the expression of Ctgf, a TGF-β activity bio-
marker and down-strain gene, in bleomycin-induced
mice. These observations combined with the results of
anti-fibrotic effects of SPARC siRNA in fibroblasts of the
Tgfbr1 knock-in mouse further support a mutually regu-
latory relationship between SPARC and TGF-β signaling.
Conclusions
Studies described here consistently demonstrated that
inhibition of SPARC with siRNA significantly reduced
collagen expression in both in vitro transgenic Tgfbr1
fibroblast model and in vivo bleomycin-induced fibrotic
mouse models. This is the first attempt to examine the
anti-fibrotic effects of SPARC inhibition using siRNA
with tissue-specific administration in skin and lungs in
vivo. The results obtained from these studies provide
favorable evidence that SPARC may be used as a bio-tar-
get for application of anti-fibrosis therapies.
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